approx. £119,000 for investigations and consultations. Using a Calprotectin® (Preventis, GmbH) point of contact FC test, it was estimated that a saving of £89,000 could be achieved. A pathway for investigating chronic diarrhea using Calprotectin® was designed and implemented in the community (population 150,000) between September 2011–March 2012. This will be presented. FC results were categorised using manufacturer cut-offs of <15 μg/g, 15–60 μg/g and >60 μg/g. Patients with FC results of 15–60 and >60 were deemed to have an inflammatory process and referred to Gastroenterology Clinics. Cost analysis was carried out using the 2010–11 tariffs for the NHS.

**Results** 142 Calprotectin® tests were carried out in Primary Care during this pilot phase. Of these, a negative result (<15 μg/g) was present in 89, with 36 tests being >60 μg/g. 3 tests were at the intermediate level and 14 tests could not be accurately reported. Negative results were managed in primary care as IBS. A monthly cost savings of £5100 was calculated taking consultation and endoscopy tariffs into account.

**Conclusion** This pilot study demonstrates the feasibility and cost effectiveness of a pathway for decision making and a point-of-care faecal calprotectin test in rationalising referrals to gastroenterologists for chronic diarrhea.

**Disclosure of Interest** A. Dhar speaker bureau with: Shire Pharmaceuticals, Warner Chilcott UK, S. Lee: None Declared, H. Borthwick: None Declared, P. Nair: None Declared, C. White: None Declared

---

**PTU-058**

**ONE YEAR LIKELIHOOD OF RELAPSE IN ULCERATIVE COLITIS (UC) IS PREDICTED BY MUCOSAL APPEARANCE BUT NOT BY FAECAL CALPROTECTIN: DATA FROM THE CODA STUDY OF ONCE DAILY VERSUS THREE DAILY ASACOL**

doi:10.1136/gutjnl-2013-304907.150

1*A B Hawthorne, 2D Gillespie, 3C Probert. Medicine, University Hospital of UK; 2SE UK Trials Unit, Cardiff; 3Institute of translational medicine, Liverpool University, Liverpool, UK

**Introduction** Faecal calprotectin (FC) has become a useful marker of mucosal healing, with studies showing raised levels predictive of relapse.\(^1,2\) These studies did not assess mucosal appearance as predictors of relapse.

**Methods** In the CODA (Colitis Once Daily Asacol®) trial of once daily (OD) Asacol® (three 800mg tablets) vs one 800mg tablet taken three times daily (TDS), 213 UC patients in remission for >4 weeks, but relapse in the past 2 years, were recruited. Baseline FC (Phical ELISA kit) was collected and rectal sigmoidoscopy (sig) score at baseline, and relapse or 1 year (using the modified Baron score: 0 = normal; 1 = erythema, decreased vascular pattern; 2 = marked erythema, absent vascular pattern, friability, erosions; 3 = spontaneous bleeding, ulceration). At entry patients had no symptoms of active disease, with a sig score of 0 or 1. Follow-up was for 1 year or until relapse (symptoms of active disease with a sig score of 2 or 3). Demographic factors, concomitant drugs, FC, sig score, CRP, and adherence were evaluated in a Cox regression model of time to relapse.

**Results** (Shown as median[IQR] unless stated otherwise). Remission duration prior to entry was 6.0 [3–12] months. Disease extent was extensive (50.0%), Lt. sided (53.2%), proctitis (15.6%). At entry FC was 78mg/kg stool [23.3–159.4], sigmoidoscopy score 0 (70.9%), 1 (29.1%). All were taking mesalazine, and 11.7% thiopurines. Baseline FC was higher if sig score was 1 (109[38–335]) than if 0 (62[21–120], \(p = 0.001\), but did not differ according to disease extent or medication (including aspirin (n = 18) and occasional NSAIDs (n = 6)). Remission rates at one year were 62% overall (68.9% in OD and 55.5% in TDS group). Factors associated with time to relapse were explored in a Cox proportional hazards model, with baseline FC dichotomised at 150mg/kg stool (as by Costa et al). Relapse risk was 2.5 times higher in those with baseline sig score 1 compared to score 0 (95% CI 1.32–4.76, \(p = 0.005\)). Age, comorbid medication, previous duration of remission, disease extent, smoking, trial medication adherence and baseline FC (cut off at 150 mg/kg stool or as a continuous variable) did not remain in the final model.

**Conclusion** In this study, sigmoidoscopy at baseline was the sole factor predicting relapse over 1 year of maintenance mesalazine 2.4g, whereas calprotectin level was not a predictor, perhaps because of wide variability in this group of patients. FC may have more value in measuring relative change in individual patients.

**Disclosure of Interest** A. Hawthorne Grant/Research Support from: CODA study supported by unrestricted grant from Warner Chilcott, D. Gillespie: None Declared, C. Probert: None Declared

**REFERENCES**


---

**PTU-059**

**ADALIMUMAB THERAPY REDUCES HOSPITALIZATION AND COLECTOMY RATES IN PATIENTS WITH ULCERATIVE COLITIS AMONG INITIAL RESPONDERS**

doi:10.1136/gutjnl-2013-304907.151

1*B G Feagan, 2W J Sandborn, 3M Yang, 4A Lazar, 5R B Thakkar, 6J Chao, 7P M Mulani. 8Robarts Research Institute, University of Western Ontario, London, ON, Canada; 9UCSD, La Jolla, CA; 10AbbVie, Abbott Park, IL, United States; 11AbbVie Deutschland, Ludwigshafen, Germany

**Introduction** Two double-blind, placebo-controlled trials (ULTRA 1 and 2) revealed that adalimumab (ADA) therapy significantly reduces hospitalisation and non-significantly decreases colectomy rates in patients with moderate to severe ulcerative colitis (UC).\(^1\)

**Methods** We assessed the effect of an ADA 160/80/40 mg treatment regimen on risk reduction of all-cause and UC-related hospitalisation and colectomy in these 2 trials among initial ADA responders. The pooled dataset included 963 patients (480 ADA, 483 placebo [PBO]). Hospitalization and colectomy events were based on safety reports reviewed by 2 gastroenterologists who were blinded to treatment. Conservatively, hospitalizations from initial ADA non-responders (per Mayo score at Week 8) through Week 8 were counted, but were censored after Week 8 to reflect the clinical practise pattern of continuing treatment in initial ADA responders. Risk and number of hospitalizations were compared between groups using person-year (PY)–based incidence rates (IRs) and Poisson regression, respectively; Z-scores were used to assess statistical differences.\(^2\)

**Results** 85% and 34% reductions in the number of patients hospitalised and number of hospitalizations for any reason, respectively, were observed with ADA therapy vs. PBO (table, \(P < 0.05\) for both comparisons). When UC-related hospitalizations were compared, reductions for rate (50%) and number (54%) of hospitalizations were both statistically significant, too.

**Conclusion** Initial ADA-responders had a significantly lower risk for UC-related and all-cause hospitalisation compared with PBO. Reduction of all-cause hospitalisation is unique for ADA compared with any other anti–tumour necrosis factor agent. A non-significantly lower colectomy rate in patients receiving ADA vs. those receiving PBO was also observed.